Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD79b-19 CAR T cells |
Synonyms | |
Therapy Description |
CD79b-19 CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting both CD79b and CD19 expressed on tumor cells, potentially leading to cytotoxicity against tumor cells and inhibition of tumor growth (PMID: 31439577). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD79b-19 CAR T cells | CD19 Immune Cell Therapy 62 | CD79b-19 CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting both CD79b and CD19 expressed on tumor cells, potentially leading to cytotoxicity against tumor cells and inhibition of tumor growth (PMID: 31439577). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |